SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced an oral and a poster presentation at the 58th American Society of Hematology Annual Meeting to be held December 3-6 in San Diego, California. The details for the oral presentation are as follows: Date and Time:Monday, December 5, 2016 at 3:15 p.m. Pacific Time Abstract Title:Durable Overall Survival Benefit in Patients = 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial Session Number:616 Session Name:Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Clinical trials of Novel Drugs and Combinations in AML Publication Number: 903 Location:Marriott Marquis San Diego Marina, San Diego Ballroom AB The full abstract can be viewed here. The details for the poster presentations are as follows: Date and Time:Saturday, December 3, 2016, 5:30 PM-7:30 PM Abstract Title:First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects Session Number: 642Session Name: CLL: Therapy, excluding Transplantation: Poster I Publication Number: 2032 Location:San Diego Convention Center, Hall GH The full abstract can be viewed here. About Sunesis Pharmaceuticals Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer. Currently, the company is focused on pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older, as well as advancing its novel kinase-inhibitor pipeline, which includes its proprietary non-covalent BTK-inhibitor, SNS-062. For additional information on Sunesis, please visit http://www.sunesis.com. SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.